Annual Report 2019

Karo Pharma takes aim at Europe

In a short period of time Karo Pharma has, through expanded strategic acquisitions and organic growth, become established as one of the leading pharmaceutical companies in the Nordics. Our ambition is to offer products that improve people’s health and quality of life. We have a commercial focus and specialize on the sales and marketing of prescription drugs (Rx) and over the counter (OTC) products for consumers. Our products are available in over 60 countries.

At Karo Pharma we strive to be cost-conscious and opportunistic. The company is growing organically with, as well as through acquisitions and investments in innovative projects with low development risk and short time to market. This strategy has resulted in solid profitability during the past few years and will play a pivotal role in strengthening our presence in Europe by positioning Karo Pharma as an attractive partner.

Press releases

1 April, 2020

Karo Pharma enters the Swiss market with direct presence by acquiring Hygis SA

Karo Pharma AB (Karo) has today acquired Hygis SA (Hygis), a Swiss distributing company with exclusive distribution rights to Karo’s…
27 March, 2020

Karo Pharma postpones the Annual General Meeting to 25 May, 2020

The board of directors of Karo Pharma Aktiebolag (”Karo Pharma”) has resolved to postpone the Annual General Meeting to 25…
2 March, 2020

Karo Pharma completes the acquisition of product portfolio from LEO Pharma

Karo Pharma Aktiebolag (“Karo Pharma”) today announces that the acquisition of the intimate care and dermatology product portfolio from LEO…

 See all press releases

Reports

1 April, 2020

Karo Pharma publishes the 2019 annual report

Today, on 1 April 2020, Karo Pharma is publishing its annual report for 2019 on the company’s website, www.karopharma.com. FOR…
19 February, 2020

Year-end report 2019

OCTOBER – DECEMBER · Net sales amounted to MSEK 649.3 (463.3). This corresponds to an increase of 40% for the…
15 November, 2019

INTERIM REPORT JANUARY – SEPTEMBER 2019

JULY – SEPTEMBER · Net sales amounted to MSEK 443.7 (395.3). This corresponds to an increase of 12% for the…

 See all reports

About Karo Pharma

Karo Pharma is a pharmaceutical company specialised in sales and marketing of prescription pharmaceuticals and over-the-counter products sold in pharmacies and retail.
Read more

Partnership

We have an opportunistic attitude to partnerships and acquisitions of companies and brands that suit our product portfolio, organization and business strategy.
Read more

Investors

We create stockholder value through regular acquisitions and investments in established products with stable earning potential.
Read more

Products

Wortie

Wortie offers effective, safe, and easy to use treatments against warts and verrucas. Wortie has a range of products with different treatment styles to fit with individual prefrances, so that it is easy to treat at home. Worties patanted cyrotheropy products is the heros of the rang, with the unique metaltip only the wart of...

Locobase

Locobase

Locobase is a well-established skincare brand, recommended by health care professionals and pharmacy staff. Locobase is an international brand being sold in around 40 countries with a strong position mainly on the Nordic market. Locobase is clinically proven to be gentle to sensitive skin and highly suitable for eczema-prone skin. Locobase is available as Repair,...

Virusseptin

Viruseptin

Viruseptin is a dual-acting cold spray that can be used for prevention and treatment of nasal and pharyngeal infections. Viruseptin effectively prevents viruses from spreading and can, if the cold has already broken out, shorten the disease period and reduce the risk of a recurring infection. Viruseptin is the first cold spray that has had...

View more products